Research on characteristics of the biopharmaceutical pipeline and on changes since 2003 includes a description of new features and recommendations for health policy decision makers.
Paul C. Nagle, BSBA
Advertisement
Articles by Paul C. Nagle, BSBA
Advertisement
Latest Updated Articles
- Review of Recent US Cost Estimates of Revascularization
October 1st 2004
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies
2
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
3
A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD
4
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
5